Vaxxas is a biotechnology startup based in Australia, founded in 2011. The company is focused on commercializing a revolutionary needle-free technology that significantly improves the performance of both current and future vaccines. This innovative approach is set to challenge the conventional methods of vaccine delivery, sparking a shift in global perspectives on vaccine possibilities. At 23 August 2023, Vaxxas received a significant $4.00M grant investment from Wellcome Trust, showcasing the strong support and confidence of prominent investors in the company's vision and technological advancements. This strategic investment not only provides significant financial backing but also serves as a validation of Vaxxas' potential to redefine the landscape of vaccine technology and delivery systems.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $4.00M | 1 |
|
23 Aug 2023 |
| Series C | $34.00M | 3 |
|
05 Dec 2022 |
| Grant | $8.20M | 1 | Australian Government | 20 Sep 2022 |
| Grant | $4.40M | 1 | Australian Government | 01 Jan 2021 |
| Grant | $22.00M | 1 | Biomedical Advanced Research and Development Authority (BARDA) | 05 Oct 2020 |
No recent news or press coverage available for Vaxxas.
We care about your data, and we'd love to use cookies make your experience better.
